Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
Inhibrx (Nasdaq: INBX) has won a significant legal victory in a trade secrets case brought by I-Mab Biopharma in the United States District Court for the District of Delaware. The jury rejected all allegations of misappropriation that were filed on March 1, 2022, against Inhibrx and its Chief Scientific Officer, Brendan Eckelman, Ph.D. The lawsuit had claimed improper access and use of proprietary information during a prior arbitration proceeding where Dr. Eckelman served as an expert witness. The verdict validates Inhibrx's independent development processes and ethical conduct in advancing its therapeutic innovations.
Inhibrx (Nasdaq: INBX) ha ottenuto una significativa vittoria legale in un caso di segreti commerciali intentato da I-Mab Biopharma presso il Tribunale Distrettuale degli Stati Uniti per il Distretto del Delaware. La giuria ha rigettato tutte le accuse di appropriazione indebita presentate il 1 marzo 2022 contro Inhibrx e il suo Chief Scientific Officer, Brendan Eckelman, Ph.D. La causa sosteneva un accesso e un uso improprio di informazioni riservate durante un precedente procedimento arbitrale in cui il Dr. Eckelman ha svolto il ruolo di esperto testimoniale. La sentenza convalida i processi di sviluppo indipendenti e la condotta etica di Inhibrx nel progresso delle sue innovazioni terapeutiche.
Inhibrx (Nasdaq: INBX) ha ganado una victoria legal significativa en un caso de secretos comerciales presentado por I-Mab Biopharma en el Tribunal de Distrito de los Estados Unidos para el Distrito de Delaware. El jurado rechazó todas las acusaciones de apropiación indebida que se presentaron el 1 de marzo de 2022 contra Inhibrx y su Director Científico, Brendan Eckelman, Ph.D. La demanda había reclamado acceso y uso indebido de información confidencial durante un procedimiento de arbitraje anterior en el que el Dr. Eckelman sirvió como testigo experto. El veredicto valida los procesos de desarrollo independientes de Inhibrx y su conducta ética en el avance de sus innovaciones terapéuticas.
Inhibrx (Nasdaq: INBX)는 델라웨어 특별 지방법원에서 I-Mab Biopharma에 의해 제기된 영업 비밀 사건에서 중요한 법적 승리를 거두었습니다. 배심원단은 2022년 3월 1일 Inhibrx와 그 최고 과학 책임자인 Brendan Eckelman, Ph.D에 대해 제기된 모든 부정사용 주장들을 기각했습니다. 이 소송은 Eckelman 박사가 전문가 증인으로 출석했던 이전의 중재 절차 중에 프로프라이어터리 정보에 대한 부적절한 접근과 사용을 주장했습니다. 이번 평결은 Inhibrx의 독립적인 개발 과정과 치료 혁신을 추진하는 윤리적 행위를 확인해 줍니다.
Inhibrx (Nasdaq: INBX) a remporté une victoire légale importante dans une affaire de secrets commerciaux portée par I-Mab Biopharma devant le tribunal de district des États-Unis pour le district du Delaware. Le jury a rejeté toutes les allégations d'appropriation qui avaient été déposées le 1er mars 2022 contre Inhibrx et son directeur scientifique, Brendan Eckelman, Ph.D. Le procès prétendait un accès et une utilisation inappropriés d'informations propriétaires lors d'une procédure d'arbitrage précédente où le Dr Eckelman avait été témoin expert. Le verdict valide les processus de développement indépendants de Inhibrx et sa conduite éthique dans l'avancement de ses innovations thérapeutiques.
Inhibrx (Nasdaq: INBX) hat einen bedeutenden rechtlichen Sieg in einem Fall von Geschäftsgeheimnissen erzielt, der von I-Mab Biopharma vor dem US-Bezirksgericht für den Bundesstaat Delaware eingereicht wurde. Die Jury wies alle Vorwürfe der unrechtmäßigen Aneignung zurück, die am 1. März 2022 gegen Inhibrx und seinen Chief Scientific Officer, Brendan Eckelman, Ph.D., erhoben wurden. Die Klage hatte unzulässigen Zugriff und die Nutzung von proprietären Informationen während eines vorherigen Schiedsverfahrens geltend gemacht, in dem Dr. Eckelman als Sachverständiger auftrat. Das Urteil bestätigt die unabhängigen Entwicklungsprozesse und das ethische Verhalten von Inhibrx bei der Förderung seiner therapeutischen Innovationen.
- Legal victory eliminates potential business risks and legal liabilities
- Company can now focus undistracted on its core business operations
- Validation of company's independent development processes
- None.
Insights
The jury verdict in favor of Inhibrx against I-Mab's trade secret misappropriation claims represents a significant legal victory that removes a substantial risk factor for the company. Trade secret litigation can be extremely costly and potentially result in significant damages, injunctive relief, or forced changes to research programs. The complete rejection of I-Mab's claims validates Inhibrx's R&D processes and intellectual property position.
The outcome protects Inhibrx's ability to continue developing its clinical pipeline without interference or potential licensing obligations. This strengthens the company's competitive position and preserves its freedom to operate. While some matters remain before the Court, the core allegations have been resolved in Inhibrx's favor, significantly reducing legal risk and associated uncertainty for investors.
I-Mab had initiated the lawsuit on March 1, 2022, alleging that Inhibrx and its Chief Scientific Officer, Brendan Eckelman, Ph.D., improperly accessed and used proprietary information related to several of I-Mab's research projects during a prior arbitration proceeding involving I-Mab, for which Dr. Eckelman served as an expert witness. However, the jury found absolutely no basis for these claims, validating Inhibrx's independent development processes and principled conduct in advancing its therapeutic innovations.
"Inhibrx was founded on the values of integrity, scientific excellence, and a commitment to advancing novel therapeutics for patients in need. This verdict is not only vindicating, disproving unfounded allegations, but also reaffirms our dedication to conducting groundbreaking research with the utmost respect for ethical boundaries," said Dr. Eckelman. "We're proud of the work we do and of the team that made this possible by upholding the highest standards."
Throughout the trial, Inhibrx demonstrated that its scientific achievements were the result of its own hard work, advanced capabilities, and innovation. Testimonies from Inhibrx's scientists highlighted the Company's deep commitment to independent development, securing proprietary knowledge, and protecting intellectual property.
Inhibrx began as a small startup with a mission to pioneer treatments that offer hope to patients battling cancer and other serious diseases. Today, as a publicly traded company with a growing portfolio of therapeutic candidates, it remains dedicated to advancing solutions for unmet medical needs while respecting the intellectual property of others.
"This outcome allows us to focus even more on what matters: delivering life-changing therapies to patients around the world," added Mark Lappe, CEO of Inhibrx. "We are grateful for the support we received throughout this process and for the opportunity to continue our work undistracted and with renewed dedication."
Inhibrx was represented by Potter Anderson & Corroon LLP and Wilson Sonsini Goodrich & Rosati PC. Certain matters remain before the Court.
About Inhibrx
Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. For more information, please visit www.inhibrx.com.
Forward Looking Statements
The Company cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: the decisiveness of the legal victory and the fact that certain matters remain before the Court; the Company's processes for development; and its ability to conduct groundbreaking research, advance solutions for unmet medical needs and deliver therapies to patients around the world. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation, risks and uncertainties regarding: the potential for any appeals or further proceedings by the Court relating to the I-Mab lawsuit; the Company's ability to advance therapeutic candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals, including whether any product candidate receives approval from the United States Food and Drug Administration, or similar regulatory authority, for an accelerated approval process; the commercialization of the Company's therapeutic candidates, if approved; the Company's ability to utilize the Company's technology platform to generate and advance additional therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering the Company's therapeutic candidates; developments relating to the Company's competitors and the Company's industry; and other risks described from time to time in the "Risk Factors" section of its filings with the
Investor and Media Contact:
Kelly D. Deck
Chief Financial Officer
ir@inhibrx.com
858-795-4260
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-prevails-in-trade-secret-case-reaffirming-its-commitment-to-integrity-and-innovation-302295830.html
SOURCE Inhibrx Biosciences, Inc.
FAQ
What was the outcome of Inhibrx (INBX) trade secret case with I-Mab Biopharma?
When did I-Mab file the lawsuit against Inhibrx (INBX)?